Home World News Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma World News Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma By Ogkologos - March 16, 2026 371 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ZSAB-neoGOLP study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among... November 8, 2024 Using Aspirin to Prevent Breast Cancer Recurrence and Targeted Therapy for... February 14, 2022 Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in... August 11, 2026 FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive Stage Small Cell... May 24, 2024 Load more HOT NEWS Neoadjuvant Treatment with Dual Immune Checkpoint Inhibitors Plus Chemotherapy Produces Numerically... New Technology System Allows Patients To Get A Mammogram And Biopsy... High-Deductible Health Plans Linked to Delayed Diagnosis and Treatment of Breast... Limited Efficacy of Nivolumab plus Ipilimumab in Adenoid Cystic Carcinomas, but...
